Cross-Sector entity
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Bayer Aktiengesellschaft, the most common co-covered peer. We currently track 1 Cross-Sector story that mention ICU Medical, all published on February 20, 2026.
1 verified story tracked
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Bayer Aktiengesellschaft, the most common co-covered peer. We currently track 1 Cross-Sector story that mention ICU Medical, all published on February 20, 2026. Each carries 54 original sources on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ICU Medical. Shared-story counts are live from our verified record — not editorial picks.
A wave of earnings reports and clinical trial results has triggered significant volatility across the healthcare and biotech sectors. While Genmab reported a decline in full-year profits, breakthrough Phase 3 results from Compass Pathways and Ocular Therapeutix highlight a sharp divergence between clinical success and market valuation.
